DIRS.INFO The most relevant business & tech news

☆ Another tech bubble bursts: 2022 has been brutal for Silicon Valley workers
▼ + stars: | 2022-11-27 | by ( David Ingram | David Ingram Covers Tech For Nbc News. | ) www.nbcnews.com time to read: +28 min

Gem: 100A maker of recruiting software, the startup cut a third of its workforce Nov. 1, The Information reported. HealthCare.com: 149The health insurance marketplace announced the job cuts Aug. 3, Miami Inno reported, citing state regulatory filings. Fabric: 120The robotics startup said July 13 that it was layoffing off 40% of them, TechCrunch reported, citing company confirmation. It affected about 300 people, the Silicon Valley Business Journal reported, citing company confirmation. Policygenius: 170The online insurance company cut about 25% of its staff, Axios reported June 6, citing company confirmation.

CNN —SpaceX is carrying a fresh haul of supplies to the International Space Station this weekend after bad weather at the launch site forced the company to wave off its first attempt. The bounty of supplies on board includes a pair of new solar arrays for the space station, dwarf tomato seeds and a range of science experiments. They will give the space station a power boost. SpaceX has launched more than two dozen resupply missions to the space station over the past decade as part of a multibillion-dollar deal with NASA. The space tomatoes will be grown inside small bags called plant pillows installed in the Vegetable Production System, known as the Veggie growth chamber, on the space station.

☆ Goldman’s official 2023 outlook is here: Where it thinks the market is headed and what to buy
▼ + stars: | 2022-11-22 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Goldman Sachs is predicting zero earnings growth in 2023, with stocks ending the next year essentially flat. The firm is pegging 2023 S & P 500 earnings-per-share flat at $224 and the index ending next year at 4,000, just over 1% from Monday's close. The bank's EPS yield for the next 12 months is 14%, while its estimated EPS will decline by 12% in 2023, according to Goldman. Walgreens's EPS yield for the next 12 months is 11% and its estimated 2023 earnings growth is 2%, Goldman found. Its next-12-month EPS yield is 7% and its estimated EPS growth for 2023 is 4%, according to Goldman.

☆ Dwarf tomato seeds will launch to ISS aboard SpaceX's next resupply flight
▼ + stars: | 2022-11-22 | by ( Ashley Strickland | ) edition.cnn.com time to read: +5 min

CNN —When SpaceX’s 26th commercial resupply mission launches Tuesday, it will carry a bounty of supplies, a pair of new solar arrays, dwarf tomato seeds and a range of science experiments to the International Space Station. The mission will also deliver ice cream and Thanksgiving-style treats, including spicy green beans, cran-apple desserts, pumpkin pie and candy corn, to the space station crew. The International Space Station Roll Out Solar Arrays, or iROSAs, will be installed outside the floating laboratory during spacewalks scheduled for November 29 and December 3. The solar arrays will give the space station a power boost. Astronauts have grown and tasted different types of lettuce, radishes and chiles on the International Space Station.

☆ Stocks making the biggest moves midday: Bath & Body Works, Norwegian Cruise Line, Macy's and more
▼ + stars: | 2022-11-17 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Bath & Body Works – Bath & Body Works' stock surged 24% after reporting per-share earnings that were more than double what analysts had anticipated. The retailer also raised its guidance for full-year per-share earnings. Norwegian Cruise Line – Shares of the cruise stock shed 6% following a double downgrade to an underperform rating from Credit Suisse. Macy's – Shares of Macy's rallied 14% after the department store reported profit and revenue that beat Wall Street's expectations. BJ's Wholesale – Shares dropped 6% despite the company reporting beats on the top and bottom lines and raising its full-year forecast for per-share earnings.

☆ Sell this medical testing stock poised to fall more than 15% from here, Citi says in downgrade
▼ + stars: | 2022-11-17 | by ( Samantha Subin | ) www.cnbc.com time to read: +1 min

It's time for investors to sell shares of Quest Diagnostics , according to Citi. Analyst Patrick Donnelly downgraded shares of the medical testing company to sell from neutral, citing risks ahead to the company earnings per share guidance and 4% to 5% long-term growth guide for its base business. Quest Diagnostics' lower operational leverage makes the company increasingly sensitive to modest cost hikes, Donnelly said. Donnelly also said investors are failing to account for how a potentially serious flu season could impact Quest Diagnostics. "Further, flu tests are more heavily conducted at the Point-of-Care vs. outsourced to labs like DGX and LH."

☆ Here are the 10 stocks we consider our core holdings in the Club portfolio — and why
▼ + stars: | 2022-11-17 | by ( Jeff Marks | ) www.cnbc.com time to read: +12 min

At the Investing Club, we generally try to keep our portfolio to around 30 stocks, give or take a few. In light of Thursday's "Monthly Meeting," we wanted to identify what we consider our 10 core holdings of the 32. We may consider a stock a core holding today but that could change three months from now. Management sees its post-separation core business growing revenues at a high single-digit clip and earnings-per-share increasing in the double digits. The stock provides a stellar dividend yield of nearly 3.5%, and the bank has plenty of excess capital to repurchase stock quarter after quarter, while other banks have paused their buybacks.

☆ It's 'early innings' in the fertility market. Here's how to play the booming business with under-the-radar names
▼ + stars: | 2022-11-17 | by ( Michelle Fox | ) www.cnbc.com time to read: +13 min

The multibillion dollar global fertility market is ripe with opportunity. For investors thinking about the fertility market, pharma firms may come to mind. In fact, the number of employers looking at fertility benefits as a "must have" has skyrocketed, she said. The global market size for fertility within the private women's health market should reach $72 billion by 2027, a report by FemTech Focus and Coyote Ventures found. Just like there were a wave of fintech companies going public, she expects fertility companies to eventually follow suit.

☆ Indonesia leader says intellectual property waiver must be widened on health issues
▼ + stars: | 2022-11-15 | by ( ) www.reuters.com time to read: 1 min

NUSA DUA, Indonesia, Nov 15 (Reuters) - Indonesia President Joko Widodo at the G20 Summit on Tuesday said an intellectual property waiver "must be widened" for all health solutions, including diagnostics and therapeutics. The president in a speech before opening a session on health also said the COVID-19 pandemic was a reminder that the world should brace for other health threats in future. Reporting by Stanley Widianto and Fransiska Nangoy; Editing by Martin PettyOur Standards: The Thomson Reuters Trust Principles.

☆ Roche's Alzheimer's drug fails to meet goal in long awaited trial
▼ + stars: | 2022-11-14 | by ( Ludwig Burger | ) www.reuters.com time to read: +4 min

Nov 14 (Reuters) - Roche said (ROG.S) its Alzheimer's drug candidate could not clearly be shown to slow dementia progression in two drug trials, failing to draw level with a recent development success by rivals Biogen (BIIB.O) and Eisai (4523.T). Within each study, volunteers were randomly assigned to receive either the injectable antibody drug gantenerumab or a placebo. The quest to develop an Alzheimer's drug, targeting beta-amyloid or other molecules, has been beset by a long list of study failures. But rival Biogen in September scored a surprise trial success with an experimental Alzheimer's drug that it developed with Eisai, rebuilding confidence among industry executives and researchers in the beta-amyloid approach. Schwan earlier this year sought to curb expectations for the Graduate trials but the head of Roche's pharma unit last month acknowledged that Biogen's success with lecanemab had reignited hopes.

☆ Apple will spend $450 million with Globalstar and others to enable emergency satellite texting
▼ + stars: | 2022-11-10 | by ( Kif Leswing | ) www.cnbc.com time to read: +2 min

Apple said Thursday it will spend $450 million with U.S. companies to enable its new emergency satellite texting feature. The majority of that money will go to Globalstar , Apple said, a Louisiana-based company that operates the satellites that make the feature possible. Apple isn't taking an equity stake in the company but it is committing to spend money for equipment and the service's operations. In September, Apple announced Emergency SOS with Satellite as a banner feature on new iPhone 14 models. Apple's payment to Globalstar will come from Apple's Advanced Manufacturing Fund, a pool of money the company uses to support U.S.-based suppliers.

☆ What Cramer is watching Tuesday — big J&J deal, Lilly guidance light, Biden scolds Big Oil
▼ + stars: | 2022-11-01 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Club holding J ohnson & Johnson (JNJ) buys Abiomed (ABMD), premier heart pumping company, in a deal valued at $16.6 billion. J & J is paying a hefty premium: $380-per-share upfront, plus extra $35-per-share if certain milestones are met. J & J juiced growth ahead of its separation into two companies: one, pharma and the other, consumer brands. This will raise the growth rate of the MedTech portion of new J & J company. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) very good: $516 million versus $470 million expected.

☆ Thermo Fisher to buy diagnostics firm Binding Site for $2.6 bln
▼ + stars: | 2022-10-31 | by ( ) www.reuters.com time to read: 1 min

Oct 31 (Reuters) - Thermo Fisher Scientific Inc (TMO.N) said on Monday it would buy specialty diagnostics firm the Binding Site Group from a group led by European private equity firm Nordic Capital in an all-cash transaction valued at 2.25 billion pounds ($2.6 billion). The Birmingham-based company's test helps detect and monitor multiple myeloma, a cancer in a type of white blood cell, and is on track to deliver more than $220 million of revenue in 2022, Thermo Fisher said. Thermo Fisher, which makes scientific instruments, expects the transaction to be completed in the first half of 2023 and boost adjusted earnings per share by 7 cents on the first full-year of ownership. Reporting by Leroy Leo and Pratik Jain in Bengaluru; Editing by Sriraj KalluvilaOur Standards: The Thomson Reuters Trust Principles.

☆ Fact Check-Boston University hybrid COVID virus kills 80% of mice, not people
▼ + stars: | 2022-10-25 | by ( Reuters Fact Check | ) www.reuters.com time to read: +6 min

The authors then infected different sets of transgenic mice designed to be susceptible to SARS-CoV-2 with one of the three strains: Omicron, the ancestral virus, or the Omi-S hybrid virus (here). In the study, 100% of mice infected with the ancestral virus strain died, while 80% of those infected with Omi-S died, and none of the mice infected with Omicron died. Others shared the claim that the Omi-S had an “80% kill rate,” without specifying whether this referred to mice or humans. The ancestral virus (the viruses as they were when introduced in Europe and the US) in this mouse model kills 100% of the animals. Early in the pandemic, the fatality rate of the ancestral virus for people in a multicountry European analysis was estimated at about 4% (here).

☆ Fungal infection list launched by WHO flags global health threat
▼ + stars: | 2022-10-25 | by ( Jennifer Rigby | ) www.reuters.com time to read: +2 min

LONDON, Oct 25 (Reuters) - The World Health Organization has drawn up the first ever list of fungal pathogens posing the greatest threat to human health, warning that some strains are increasingly drug-resistant and becoming more widespread. The U.N. body, which has similar lists for viruses and bacteria, said fungal infections and their increasing resistance to treatment were a growing risk. Fungal infections often strike people who are already severely ill, like cancer or tuberculosis patients, and rates jumped among hospitalized COVID-19 patients during the pandemic. The list divides the pathogens into three categories based on their potential impact and data on their resistance risk: critical, high and medium priority. The medium group lists a number of other fungi, including Coccidioides spp and Cryptococcus gattii.

☆ In internal meetings and leaked documents, Amazon dreams of taking on Google's DeepMind by using machine learning to revolutionize drug discovery, genomics, clinical trials and more
▼ + stars: | 2022-10-21 | by ( Eugene Kim | ) www.businessinsider.com time to read: +7 min

Amazon held an internal machine learning conference last week. The deployment of machine learning across healthcare was a major topic. The event was all about machine learning, a powerful type of artificial intelligence that has already transformed Amazon's business and those of other tech giants. He was joined at last week's Amazon Machine Learning Conference by Amazon's chief medical officer Taha Kass-Hout. One of the workshops was about machine learning for "human health."

☆ Tesla and Truss, 5% and 150
▼ + stars: | 2022-10-20 | by ( ) www.reuters.com time to read: +4 min

A Tesla model 3 car is seen in their showroom in Singapore October 22, 2021. read more The latest European tech sector earnings on Thursday were downbeat, too. Bank of England Deputy Governor Ben Broadbent said the BoE would respond to changes in Truss's tax and spending policies. read moreKey developments that should provide more direction to U.S. markets later on Thursday:* European Union summit in Brussels* U.S. Oct Philadelphia business index. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

☆ Stocks making the biggest moves midday: Allstate, AT&T, IBM, Tesla and more
▼ + stars: | 2022-10-20 | by ( Carmen Reinicke | ) www.cnbc.com time to read: +5 min

AT&T – The telecom giant's stock jumped 7% after the company surpassed earnings and revenue estimates for the recent quarter. AT&T's wireless revenue rose 5.6%. Tesla – Shares of electric automaker Tesla fell 6% Thursday, a day after the company reported third-quarter earnings that fell short of Wall Street's expectations for revenue. Freeport McMoRan – Shares of Freeport McMoRan jumped more than 3% after the mining company reported earnings Thursday. The company reported third-quarter earnings per share of $2.36 versus the StreetAccount estimate of $2.19.

☆ Premarket stocks: The Fed isn't about to back down from its inflation fight
▼ + stars: | 2022-10-20 | by ( Julia Horowitz | ) edition.cnn.com time to read: +5 min

A version of this story first appeared in CNN Business’ Before the Bell newsletter. London CNN Business —Twelve days from now, the Federal Reserve will meet again, and expectations for the central bank’s next moves are firming up. The consensus among investors: Persistently hot inflation means the Fed will need to continue with its string of aggressive interest rate hikes, which is unprecedented in the modern era. In an interview with Reuters on Friday, St. Louis Fed President James Bullard said inflation had become “pernicious,” which means that “frontloading” larger rate hikes is logical. But with two quarters of disappointing deliveries caused by supply chain issues and Covid-related shutdowns in China, that goal has looked increasingly out of reach, my CNN Business colleague Chris Isidore reports.

☆ Danaher shares slide after knockout quarter. Here's why it's a buying opportunity
▼ + stars: | 2022-10-20 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

That trend is expected to continue and result in high-single-digit core revenue growth for the bioprocessing business for the full year. Driving the gains was 30% core revenue growth at Cepheid as the businesses respiratory testing revenue of about $875 million exceeded management's expectations of roughly $325 million. Guidance Management expects overall core revenue growth to be flat to down low-single-digits for the fourth quarter. For the full year 2022, management continues to forecast base business core revenue growth in the high-single-digit percent range. That's better than the 5.9% full-year core revenue growth expected on the Street.

☆ 3 of our stocks, including J&J, report earnings this week. Here's what we'll be watching
▼ + stars: | 2022-10-17 | by ( Jim Cramer | ) www.cnbc.com time to read: +6 min

Here's how we're thinking about J & J, P & G and Danaher heading into their prints, along with Wall Street estimates provided by Refinitiv. When reporting its second quarter, back in July , J & J took down its full-year profit outlook due to currency headwinds. In late September, J & J announced that Kenvue would be the name of the standalone consumer health company. Plus, J & J is a classic defensively oriented stock. The Johnson & Johnson logo is displayed outside the company's headquarters in New Brunswick, New Jersey, Aug. 1, 2020.

☆ October's wild trading could give way to a new stock rally, as earnings roll out in the week ahead
▼ + stars: | 2022-10-14 | by ( Patti Domm | In | ) www.cnbc.com time to read: +8 min

But Emanuel sees the chance for a 17% to 20% rally in the S & P 500. The S & P 500 was down about 0.9% for the week, as of Friday afternoon, and it was hovering just above 3,600. S & P 500 earnings are expected to grow by 3.6% for the third quarter, based on actual reports and estimates, according to Refinitiv. Without the boost from more than doubling profits from energy companies, S & P earnings would decline by 3.1%. Week ahead calendar Monday Earnings: Bank of America , Bank of NY Mellon, Charles Schwab 8:30 a.m.

☆ ‘Africa on its own’: Little help in epidemics, says official
▼ + stars: | 2022-10-13 | by ( Associated Press | ) www.nbcnews.com time to read: +3 min

Africa must plan to respond effectively to disease outbreaks without international help, a top public health official said Wednesday, warning that the continent of 1.3 billion people is “on its own” during pandemics. “This is not the first outbreak of the Sudan strain of Ebola virus here in Africa and particularly here in Uganda,” he said. He said no help has come to Africa, where more monkeypox deaths have been reported this year than anywhere in the world. “Recently, during the pandemic, when we saw the number of monkeypox cases growing here in Africa, we issued a global alert but no help came to Africa,” he said. “In fact, today, as we see the tail end of the pandemic, there’s still no help coming to Africa for monkeypox.

☆ These are the rare inflation-busting stocks that are in the green this year
▼ + stars: | 2022-10-13 | by ( Samantha Subin | ) www.cnbc.com time to read: +2 min

These stocks have managed to increase gross margins in the past year despite rising costs. What's more, these stocks are also less volatile than the overall stock market and are in the green for the year. Here are the 17 rare stocks that came up after searching a FactSet database of 1,500 stocks. Cal-Maine Foods saw the largest increase in margins over the last year, rising by 31 percentage points. Despite surging inflation, Coterra grew margins by 27.1 percentage points and Exxon by 4 percentage points.

☆ Diagnostics firm Bio-Rad in talks to merge with Qiagen - WSJ
▼ + stars: | 2022-10-10 | by ( ) www.reuters.com time to read: +1 min

Oct 10 (Reuters) - California-based diagnostics company Bio-Rad Laboratories (BIO.N) is in talks to merge with Qiagen NV (QIA.DE), the Wall Street Journal reported on Monday, citing people familiar with the matter. U.S-listed shares of Qiagen rose 8% while Bio-Rad fell nearly 10% after the report. Register now for FREE unlimited access to Reuters.com RegisterBio Rad, which manufactures and supplies products such as laboratory apparatus, instruments and diagnostics, has a market-cap of $12.85 billion. Both Qiagen and Bio-Rad did not immediately respond to Reuters' requests for comments. Register now for FREE unlimited access to Reuters.com RegisterReporting by Bhanvi Satija in Bengaluru; Editing by Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "Diagnostics"

25 mentions found